Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune's ...

Replimune Group Inc (NASDAQ:REPL) surged 60% in premarket trading after the U.S. Food and Drug Administration (FDA) accepted the company’s resubmission of its Biologics License Application (BLA) for ...